Neurodegenerative Disease Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Global Neurodegenerative Disease Market Report is Segmented by Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington's Disease, and Other Indication Types), Drug Type (N-Methyl-D-Aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, and Other Drug Types), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Sizes and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

Neurodegenerative Disease Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Neurodegenerative Disease Industry Overview

The market is semi-consolidated due to the presence of a few major market players. The major players adopt strategic methods such as mergers and acquisitions, partnerships and collaborations, investments in research and development activities, and new product launches to withstand the global competitive rivalry. Some major market players are AbbVie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Pfizer Inc., Teva Pharmaceuticals, Novartis AG, and UCB SA.

Neurodegenerative Disease Market Leaders

  1. Boehringer Ingelheim International GmbH

  2. UCB SA

  3. Novartis AG

  4. Teva Pharmaceutical

  5. Merck & Co Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Neurodegenerative Disease Market Concentration